Our finding that all ERα signalling is AF-2-dependent provides a molecular basis for the breast specific efficacy of the widely used breast cancer therapeutic, tamoxifen, which is an AF-2 antagonist but AF-1 agonist47. This evidence concerns the gene ESR1 and breast carcinoma.